NCT03387475 (LODEFI) is a Phase 2 clinical trial of Deferasirox in Myelodysplasia, sponsored by University Hospital, Grenoble.

Who is sponsoring NCT03387475?

NCT03387475 is sponsored by University Hospital, Grenoble.

What drugs are being tested in NCT03387475?

Interventions in NCT03387475: Deferasirox.

What condition does NCT03387475 study?

NCT03387475 studies Myelodysplasia.

Is NCT03387475 still recruiting?

NCT03387475 is currently completed. Last updated 16 December 2024.

Last reviewed 2024-12-16 · How we verify

NCT03387475: LODEFI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Completed Phase 2 Last updated 16 December 2024

What this trial tests

Phase 2 trial testing Deferasirox in Myelodysplasia in 39 participants. Completed in 1 October 2024.

Timeline

20 February 2018

Primary endpoint
1 October 2024

1 October 2024

Quick facts

Lead sponsor	University Hospital, Grenoble
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	20 February 2018
Primary completion	1 October 2024
Estimated completion	1 October 2024
Sites	1 location across France

Drugs / interventions tested

Deferasirox (DEFERASIROX) — full drug profile →

Conditions studied

Myelodysplasia — all drugs for Myelodysplasia →

Sponsor

University Hospital, Grenoble

Who can join

Adults 18 to 100, any sex, with Myelodysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with low-risk MDS verifying the eligibility criteria may be included in the study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting ferroptosis opens new avenues for the development of novel therapeutics.
Sun S, Shen J, Jiang J, Wang F, et al · · 2023 · cited 380× · PMID 37735472 · DOI 10.1038/s41392-023-01606-1
Ferroptosis: mechanisms and therapeutic targets.
Zhou Q, Meng Y, Le J, Sun Y, et al · · 2024 · cited 32× · PMID 39568772 · DOI 10.1002/mco2.70010
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S, Kosmider O, Maloisel F, Drenou B, et al · · 2019 · cited 18× · PMID 30287621 · DOI 10.3324/haematol.2018.203158
Understanding the Potential and Risk of Bacterial Siderophores in Cancer.
Pita-Grisanti V, Chasser K, Sobol T, Cruz-Monserrate Z. · · 2022 · cited 12× · PMID 35785195 · DOI 10.3389/fonc.2022.867271
Lower-risk myelodysplastic syndromes: Current treatment options for anemia.
Meunier M, Park S. · · 2022 · cited 9× · PMID 36467818 · DOI 10.1002/jha2.523
Ferroptosis: Iron-mediated cell death linked to disease pathogenesis.
Zhang X, Hu Y, Wang B, Yang S. · · 2024 · cited 7× · PMID 38808552 · DOI 10.7555/jbr.37.20230224
Harnessing ferroptosis to transform glioblastoma therapy and surmount treatment resistance.
Singh S, Mohapatra I, Barik D, Zheng H, et al · · 2025 · cited 5× · PMID 41057317 · DOI 10.1038/s41420-025-02744-x
Low-risk MDS-A spotlight on precision medicine for <i>SF3B1-</i>mutated patients.
Burke S, Chowdhury O, Rouault-Pierre K. · · 2025 · cited 1× · PMID 40124717 · DOI 10.1002/hem3.70103

Verify or expand the search:

Other trials of Deferasirox

Trials testing the same drug.

NCT07023666 — Early Screening and Treatment of Heart Complication in Sickle Cell Disease · Phase 2 · recruiting
NCT04423237 — Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT · completed
NCT03920657 — Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Ove · Phase 2 · terminated
NCT03372083 — Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis · Phase 4 · completed
NCT02943668 — Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or · Phase 2 · terminated

Other recruiting trials for Myelodysplasia

Currently open trials in the same condition.

NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT05735717 — MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies · Phase 2 · recruiting
NCT04202835 — ATG Plus PTCy vs ATG for CGVHD Prophylaxis · Phase 2 · active not recruiting
NCT03674411 — Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · Phase 2 · active not recruiting
NCT03314974 — Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · Phase 2 · recruiting

Other University Hospital, Grenoble trials

Trials by the same sponsor.

NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03387475 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
Last refreshed: 16 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03387475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing